Phase II Trial of GW572016 in Patients With Recurrent Prostate Cancer as Evident By a Rising PSA.

Trial Profile

Phase II Trial of GW572016 in Patients With Recurrent Prostate Cancer as Evident By a Rising PSA.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2015

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Apr 2012 Actual end date (July 2009) added as reported by ClinicalTrials.gov.
    • 22 Mar 2010 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top